MGC Pharmaceuticals Ltd's (ASX:MXC)(OTCMKTS:MGCLF) managing director Roby Zomer and clinical research officer Nadya Lisovoder discuss the next steps towards commercialising its anti-inflammatory treatment ArtemiC following the recent positive interim results from a Phase II clinical trial on COVID-19 infected patients. The Phase II double-blind, placebo-controlled clinical trial met all the primary objectives with all 10 patients in the treatment group showing significant improvement.
MGC Pharma team discuss positive interim results from ArtemiC in Phase II trial on COVID-19
Quick facts: MGC Pharmaceuticals Ltd
Price: 0.024 AUD
Market Cap: $39.38 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE